BioPharma Resources

Drug Trial Radar · NCT06057571

Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

A Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Oral TT-00420 (Tinengotinib) Tablets in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Prior Treatment of Chemotherapy and FGFR Inhibitor

Last checked: Nov 19, 2026Latest source record: Aug 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 17, 2023

Primary completion

Jul 27, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase II, open-label, multicenter study to evaluate the efficacy and safety of oral TT-00420 (Tinengotinib) tablets in subjects with cholangiocarcinoma who failed or relapsed to prior treatment of chemotherapy and FGFR Inhibitor.

Conditions

  • Cholangiocarcinoma Metastatic

Interventions

  • TT-00420 (tinengotinib)Drug

    TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by BICRTime frame: Through study completion, an average of 1 year

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Tsinghua Changgeng Hospital

    Beijing, China

  • Fudan University Shanghai Cancer Hospital

    Shanghai, China

  • Zhongshan Hospital

    Shanghai, China

  • Tianjin medical university cancer institute & hospital

    Tianjin, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Shenzhen Qianhai Shekou Free Trade Zone hospital

    Shenzhen, Guangdong, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Zhongnan hospital of Wuhan University

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Central Hospital Affiliated to Shangdong First Medical University

    Jinan, Shandong, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Eastern Hepatobiliary Surgery Hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.